Thursday, 25 November 2010

Neptune Subsidiary Reports Dramatic Results

Neptune Technologies & Bioresources
Basic Shares: 40.2 million
Fully diluted: 43.1 million


Neptune's 60% owned subsidiary, Acasti Pharma, reported Nov. 25th that its drug candidate, CaPre, outperformed the well-established fish oil based prescription drug, Lovaza, in a number of critical animal lab tests.

First, a low daily human equivalent dose of 1 gram of CaPre (krill-oil based) was given to laboratory rats and that resulted in a reduction of bad cholesterol by 40% and an increase in good cholesterol levels of 180%.

Comparatively, 4 grams of Lovaza showed no significant effect, Acasti reported.

Second, a lower daily human equivalent of 0.5 grams of CaPre proved to be as efficient as 4 grams of Lovaza in reducing triglyceride levels by 40-50% in obese rats with severe diabetes and high triglycerides, Acasti reported.
Cholesterol and triglycerides are a type of blood fat that can cause crippling diseases when they are in very high amounts.
"We believe that CaPre(TM) is in a much better position to improve the compliance of patients and help the treating physician," said Acasti President Dr. Tina Sampalis. "This latest benchmarking program gives us a a great deal of confidence regarding the upcoming phase 11 clinical trial for which we recently submitted a clinical trial application in Canada," she added.

Lovaza(R) is the only FDA approved prescription omega-3 fish oil solely indicated for the treatment of sever hypertriglyceridemia (very high triglycerides.)

According to market research firm IMS Health, global sales of Lovaza(R) hit $1 billion in 2009, with nearly $800 million of those sales taking place in the United States.

In 2007, GlaxoSmithKline bought the USA rights to Lovaza(R) through the purchase of Reliant Pharmaceuticals Inc. for $1.65 billion.

To view the entire news release, please click here.

An online investors site called Proactive Investors picked up on the news and noted at the time of its story that Neptune shares had climbed 22% on the news.
To see its report please click here.